Pharmacokinetic and pharmacodynamic assessment of oral nicotinamide in the NEAT clinical trial for early Alzheimer’s disease

Pharmacokinetic and pharmacodynamic assessment of oral nicotinamide in the NEAT clinical trial for early Alzheimer’s disease

Abstract Background Nicotinamide, a form of B3 vitamin, is an NAD+ precursor that reduces pTau231 levels via histone deacetylase inhibition in murine models of Alzheimer’s disease (AD). A recent phase 2a randomized placebo-controlled trial tested high-dose oral nicotinamide for the treatment of earl...

Full description

Saved in:
Bibliographic Details
Main Authors: Gabriel L Ketron, Felix Grun, Joshua D Grill, Howard H Feldman, Robert A Rissman, Gregory J Brewer
Format: Article
Language:English
Published: BMC 2025-03-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer disease clinical trial
Nicotinamide
Pharmacokinetics
Plasma
CSF
Methyl-nicotinamide
Online Access:https://doi.org/10.1186/s13195-025-01693-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13195-025-01693-y

Similar Items